Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 145040
Corporate User License Price USD 6000
Corporate User License Price INR 435120
Site License Price USD 4000
Site License Price INR 290080
Request a Quote

Report Title

Interstitial Cystitis-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Interstitial Cystitis-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Interstitial Cystitis-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Interstitial Cystitis-Pipeline Review, H1 2017



Executive Summary

Interstitial Cystitis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis-Pipeline Review, H1 2017, provides an overview of the Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline landscape.

Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 1, 6 and 1 respectively.

Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interstitial Cystitis (Painful Bladder Syndrome)-Overview

Interstitial Cystitis (Painful Bladder Syndrome)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Interstitial Cystitis (Painful Bladder Syndrome)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interstitial Cystitis (Painful Bladder Syndrome)-Companies Involved in Therapeutics Development

Allergan Plc

Aquinox Pharmaceuticals Inc

Astellas Pharma Inc

BELLUS Health Inc

Kytogenics Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

Merck & Co Inc

UCB SA

Urigen Pharmaceuticals Inc

Xigen SA

Interstitial Cystitis (Painful Bladder Syndrome)-Drug Profiles

(heparin + lidocaine hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AF-219-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQX-1125-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6294-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-5937-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimapitide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-16357-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-08-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mesalamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URG-801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interstitial Cystitis (Painful Bladder Syndrome)-Dormant Projects

Interstitial Cystitis (Painful Bladder Syndrome)-Discontinued Products

Interstitial Cystitis (Painful Bladder Syndrome)-Product Development Milestones

Featured News & Press Releases

Oct 03, 2016: Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer

Sep 06, 2016: Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome

May 25, 2016: Aquinox Announces Executive Appointments

May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results

May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego

Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA

Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration

Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference

Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis

Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS

Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC

Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC

Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis

May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms

Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Allergan Plc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Aquinox Pharmaceuticals Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Astellas Pharma Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by BELLUS Health Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Kytogenics Pharmaceuticals Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Lipella Pharmaceuticals Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Merck & Co Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by UCB SA, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Urigen Pharmaceuticals Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Xigen SA, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Dormant Projects, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Allergan Plc, Aquinox Pharmaceuticals Inc, Astellas Pharma Inc, BELLUS Health Inc, Kytogenics Pharmaceuticals Inc, Lipella Pharmaceuticals Inc, Merck & Co Inc, UCB SA, Urigen Pharmaceuticals Inc, Xigen SA


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand